随着2025年年报陆续披露,A股生物医药企业喜忧参半,业绩分化明显。 截至4月6日晚间,A股市场共有112家生物医药企业披露年报,60家归母净利润同比增长,其中40家营收和归母净利润双增;52家归母净利润同比下滑,其中29家营收和归母净利润双降。 部分药企因为创新药商业化兑现和对外许可(BD)收入增加驱动业绩增长,也有部分药企因为优化和调整策略进行转型而业绩承压;中药企业情况也类似,产品销量...
Source Link随着2025年年报陆续披露,A股生物医药企业喜忧参半,业绩分化明显。 截至4月6日晚间,A股市场共有112家生物医药企业披露年报,60家归母净利润同比增长,其中40家营收和归母净利润双增;52家归母净利润同比下滑,其中29家营收和归母净利润双降。 部分药企因为创新药商业化兑现和对外许可(BD)收入增加驱动业绩增长,也有部分药企因为优化和调整策略进行转型而业绩承压;中药企业情况也类似,产品销量...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.